Abbvie Inc (ABBV)

$223.07 -4.16 (-1.83%)
Market Cap 401.47B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 22.07
Forward PE 15.73
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 4,841,176
Avg Vol 6,206,208
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 85%
Beta 0.32
Analysts Strong Sell
Price Target $251.55

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
BuyDFTX
BuyDFTX Jun. 8 at 6:43 PM
$ABBV $260 📈
0 · Reply
focafoca99
focafoca99 Jun. 8 at 12:50 PM
$ABBV showcases new blood cancer data at the EHA 2026 Congress. https://www.rapidticker.com/news/abbv-abbvie-presents-new-data-across-e055e0
0 · Reply
HydrogenH2
HydrogenH2 Jun. 8 at 10:28 AM
$ABBV Are we Topping yet ??
0 · Reply
Scanlz
Scanlz Jun. 8 at 12:24 AM
$ABBV when $500 per share 😁
0 · Reply
Blockwave1
Blockwave1 Jun. 7 at 9:39 PM
🤙🚨Telegram channel: https://t.me/BlockWave10 🚨 06/08/2026 WATCHLIST 🚨 Outside Bar (Daily) 📊 🍏 $AAPL 📈 Calls Above: $315.17 📉 Puts Below: $307.15 Outside Bar (Weekly) 📊 🩺 $ABBV 📈 Calls Above: $230.47 📉 Puts Below: $208.99 Inside Bar (Daily) 📊 🏠 $HD 📈 Calls Above: $320.75 📉 Puts Below: $308.11 🦺 $M 📈 Calls Above: $23.60 📉 Puts Below: $21.84
0 · Reply
Giuseppe7
Giuseppe7 Jun. 6 at 11:55 AM
$ABBV
0 · Reply
maphere
maphere Jun. 5 at 5:18 PM
$RGNX $ABBV Abbvie next week at GS conference. A coordinated PR with RGNX on 1st dosed patient ahead of the CTS Retina conference next weekend will bring a lot of visibility to the program. Perfect time for Abbvie to highlight this program at GS.
1 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Jun. 5 at 4:25 PM
$ABBV up? What’s going on here
1 · Reply
Game_Day
Game_Day Jun. 5 at 1:28 PM
$ABBV ☀️Todays goals 228.62 229.28 231.26
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 9:28 AM
$ABBV Share Price: $224.91 Contract Selected: Jun 26, 2026 $225 Calls Buy Zone: $4.83 – $5.97 Target Zone: $8.91 – $10.89 Potential Upside: 74% ROI Time to Expiration: 20 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on ABBV
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 8, 2026, 8:00 AM EDT - 8 hours ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 7:04 PM EDT - 4 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Jun 3, 2026, 3:30 AM EDT - 5 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 2, 2026, 8:00 AM EDT - 6 days ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie announces EC authorizes expanded label for Venclyxto

2026-05-29T13:20:36.000Z - 10 days ago

AbbVie announces EC authorizes expanded label for Venclyxto

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 29, 2026, 8:00 AM EDT - 10 days ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 6:18 PM EDT - 11 days ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 12 days ago

US FDA approves AbbVie's rare blood cancer drug

FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm

2026-05-27T19:25:11.000Z - 12 days ago

FDA approves AbbVie’s Decnupaz for blastic plasmacytoid dendritic cell neoplasm

AbbVie reports positive CHMP opinion for Maviret

2026-05-22T12:12:15.000Z - 17 days ago

AbbVie reports positive CHMP opinion for Maviret

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 22, 2026, 8:00 AM EDT - 17 days ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 6:46 PM EDT - 17 days ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

2026-05-21T20:19:37.000Z - 18 days ago

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 21, 2026, 4:10 PM EDT - 18 days ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-15T12:51:42.000Z - 24 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

2026-05-14T20:15:24.000Z - 25 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

AbbVie price target raised to $298 from $294 at Piper Sandler

2026-05-14T11:07:12.000Z - 25 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 2:20 PM EDT - 26 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 4 weeks ago

AbbVie Transcript: AGM 2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 6, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

2026-05-05T12:32:52.000Z - 4 weeks ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

May 5, 2026, 8:05 AM EDT - 4 weeks ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

AbbVie price target raised to $236 from $232 at Evercore ISI

2026-05-04T12:13:35.000Z - 5 weeks ago

AbbVie price target raised to $236 from $232 at Evercore ISI

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 3:05 PM EDT - 5 weeks ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

Big Pharma M&A set for mega year as patent expiries drive deal urgency

May 1, 2026, 10:03 AM EDT - 5 weeks ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 3:00 PM EDT - 5 weeks ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T18:00:46.000Z - 5 weeks ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

AbbVie price target raised to $265 from $262 at Canaccord

2026-04-30T13:31:03.000Z - 5 weeks ago

AbbVie price target raised to $265 from $262 at Canaccord

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 30, 2026, 9:00 AM EDT - 5 weeks ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:15:57.000Z - 5 weeks ago

AbbVie upgraded to Buy at BofA on durable growth

AbbVie upgraded to Buy from Neutral at BofA

2026-04-30T10:14:18.000Z - 5 weeks ago

AbbVie upgraded to Buy from Neutral at BofA

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Earnings Call Transcript: Q1 2026

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Earnings release: Q1 2026

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Quarterly report: Q1 2026

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 5 weeks ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:50 AM EDT - 5 weeks ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 5 weeks ago

AbbVie Reports First-Quarter 2026 Financial Results

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 28, 2026, 7:00 AM EDT - 5 weeks ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 27, 2026, 8:05 AM EDT - 6 weeks ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 6 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 23, 2026, 4:05 PM EDT - 6 weeks ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 6 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 6 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 7 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 7 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 2 months ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 2 months ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 2 months ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 2 months ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 2 months ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 2 months ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 2 months ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 2 months ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 2 months ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 2 months ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 2 months ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 3 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 11:20 AM EDT - 3 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 3 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 3 months ago

AbbVie Proxy statement: Proxy Filing

BuyDFTX
BuyDFTX Jun. 8 at 6:43 PM
$ABBV $260 📈
0 · Reply
focafoca99
focafoca99 Jun. 8 at 12:50 PM
$ABBV showcases new blood cancer data at the EHA 2026 Congress. https://www.rapidticker.com/news/abbv-abbvie-presents-new-data-across-e055e0
0 · Reply
HydrogenH2
HydrogenH2 Jun. 8 at 10:28 AM
$ABBV Are we Topping yet ??
0 · Reply
Scanlz
Scanlz Jun. 8 at 12:24 AM
$ABBV when $500 per share 😁
0 · Reply
Blockwave1
Blockwave1 Jun. 7 at 9:39 PM
🤙🚨Telegram channel: https://t.me/BlockWave10 🚨 06/08/2026 WATCHLIST 🚨 Outside Bar (Daily) 📊 🍏 $AAPL 📈 Calls Above: $315.17 📉 Puts Below: $307.15 Outside Bar (Weekly) 📊 🩺 $ABBV 📈 Calls Above: $230.47 📉 Puts Below: $208.99 Inside Bar (Daily) 📊 🏠 $HD 📈 Calls Above: $320.75 📉 Puts Below: $308.11 🦺 $M 📈 Calls Above: $23.60 📉 Puts Below: $21.84
0 · Reply
Giuseppe7
Giuseppe7 Jun. 6 at 11:55 AM
$ABBV
0 · Reply
maphere
maphere Jun. 5 at 5:18 PM
$RGNX $ABBV Abbvie next week at GS conference. A coordinated PR with RGNX on 1st dosed patient ahead of the CTS Retina conference next weekend will bring a lot of visibility to the program. Perfect time for Abbvie to highlight this program at GS.
1 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Jun. 5 at 4:25 PM
$ABBV up? What’s going on here
1 · Reply
Game_Day
Game_Day Jun. 5 at 1:28 PM
$ABBV ☀️Todays goals 228.62 229.28 231.26
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 9:28 AM
$ABBV Share Price: $224.91 Contract Selected: Jun 26, 2026 $225 Calls Buy Zone: $4.83 – $5.97 Target Zone: $8.91 – $10.89 Potential Upside: 74% ROI Time to Expiration: 20 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
biolover
biolover Jun. 5 at 6:07 AM
$VKTX  CEO confirmed high awareness of their obesity program across industry and high interest by BP .. essentially what we have been hearing from the likes of $ABBV $AMGN $NVO $BMY and likely others. Also his expectation for low GI issues with maintenance dosing in trial . Early cohort on this trial entered in Oct - Nov time line so good portion would have been already on monthly or q 2 wk dosing by now. Small trial and CEO should get timely reporting. This CEO has a history of giving clues as he hinted about higher GI issues with oral phase 2 ( turned out due to 4 large pills for 120 mg ) wks prior to reporting. Now he is upbeat on maintenance tolerability. Sounds like at least no vomit issue with first 21 wks despite more rapid escalation vs phase 3. ( I know there is no vomit issue with the vanquish program at more than one site as posted earlier ) I think all the slight delay with amylin likely to get oral amylin going. Based on his previous statements.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 5 at 3:33 AM
$SLS $RVMD While we are seeing Near Miraculous ALL Pooled REGAL P3 Survival, Best Available Treatment (BAT) for the Control ARM, Aza+Ven/ Onureg + Ven IV/Sub q/Oral - 7 dosing schema - Aza_VEN - Recently FAILED the VIALE- M Phase 3 Trial for CR1 First Remission Patients, conducted by $ABBV -BAT for the SLS Phase 3 CR2 Maintenance Trial -FAILED the CR1 Maintenance Phase 3 GPs has proven effective in Preventing Relapse and Extending Survival in ALL Prior Trials, Including 2 Phase 2 AML Remission Maintenance Trials. it is Not Complicated.
0 · Reply
khalid44
khalid44 Jun. 4 at 7:56 PM
$ABBV $AMGN $HOOD
0 · Reply
Game_Day
Game_Day Jun. 4 at 7:45 PM
$ABBV 🔥 expected to reach higher tomorrow + $AMGN $HOOD gone
0 · Reply
Options_Destroyer
Options_Destroyer Jun. 4 at 7:40 PM
$ABBV $AMGN $HIMS will continue higher . keep them all
0 · Reply
Game_Day
Game_Day Jun. 4 at 4:34 PM
$ABBV (EV+) Trending new 90D highs see latest news JUNE 2 Currently Seeking 224.24 test https://news.abbvie.com/?utm_source=chatgpt.com
0 · Reply
khalid44
khalid44 Jun. 4 at 9:21 AM
$ABBV The Best Stocks to Invest $500 in Right Now Prosper Junior Bakiny, The Motley Fool Thu, June 4, 2026 at 10:05 AM GMT+3 5 min read Some investors are avoiding the healthcare sector right now due to its lagging the market in recent years and its somewhat uncertain outlook. However, this bearish sentiment could mean there are attractive opportunities to buy shares of top healthcare stocks on the dip. Here are two of my favorite picks: AbbVie (NYSE: ABBV) and Vertex Pharmaceuticals (NASDAQ: VRTX). These two not only have outstanding businesses but have also moved in the wrong direction this year despite solid prospects, making them excellent stocks to buy right now with $500 (make sure it's not saved for emergencies). Read on to find out more.
0 · Reply
khalid44
khalid44 Jun. 3 at 7:42 PM
$ABBV 240
0 · Reply
CarolineC
CarolineC Jun. 3 at 7:16 PM
$ABBV research for Alzheimers
0 · Reply
Quantumup
Quantumup Jun. 3 at 6:50 PM
Wolfe⬇️ $ABVX's PT to $136 (was $176), reiterated Outperform and said: Since our last report where we expected a modest rebound (ABVX from $130/sh to $90/sh postmarket), the stock was punished further and closed below $73/ sh on Monday. JNJ - $PTGX $ABBV CRNX CLDX Here's what Wolfe Research went on to say: https://x.com/Quantumup1/status/2062244718101041538?s=20
0 · Reply
P0rNsTaR
P0rNsTaR Jun. 3 at 5:20 PM
$ABVX a drug 40% effective. Best in class. Better than injectables. $JNJ $LLY $ABBV https://www.biopharmadive.com/news/abivax-obefazimod-abtect-ulcerative-colitis-results-cancer/821685/
0 · Reply
DefenseMania
DefenseMania Jun. 2 at 10:31 PM
$ABBV $AMGN $META $NVDA
0 · Reply